Home / Market News / $SILO
fiscal.ai Corporate Catalyst Impact 95/100 ● negative

Silo Pharma Reports Third Quarter 2026 Financial Results

Nov 15, 2026, 2:09 PM UTC · Primary ticker $SILO

Silo Pharma reported a significant decline in its financial performance for Q3 2026, with zero revenue compared to $10,000 in the prior year and an increased operating loss of $1.2 million. Despite a seemingly improved EPS of -$0.21 from -$1.79, the underlying operational results indicate a deteriorating financial position, which is a strong negative signal for investors.

Silo Pharma's Q3 2026 financial results reveal a concerning trend: the company generated zero revenue, a sharp drop from $10,000 in the same period last year, and its operating loss widened to $1.2 million. While the diluted EPS improved from -$1.79 to -$0.21, this is likely due to non-operational factors or a lower share count, as the core business performance has clearly deteriorated. This news is highly negative for current shareholders and potential investors, indicating a lack of commercial progress and continued cash burn. In the short term, this will likely lead to a significant sell-off in SILO stock. Long-term implications include increased pressure on the company to secure additional funding or demonstrate a viable path to revenue generation, with the key risk for traders being further dilution or even bankruptcy if the financial trajectory doesn't reverse.

$SILO negative Zero revenue, increased operating loss
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.